儿童期至青春期复发性腹痛的患病率与进展
基于瑞典4089名儿童的前瞻性出生队列,分析2455名完成1、2、12、16岁随访者,发现26.2%儿童至少一个时间点报告复发性腹痛(RAP),12岁RAP者44.9%持续至16岁,且16岁时RAP、任何AP-FGID和IBS风险分别增加2.2、2.6、3.2倍,而早期幼儿RAP无显著关联。
要点
- 12岁RAP是16岁RAP、AP-FGID和IBS的显著风险因素。
- 约44.9%的12岁RAP儿童症状持续至16岁。
- 幼儿期RAP与青春期结局无显著关联。
核心结论
- 12岁时的复发性腹痛是16岁时复发性腹痛、任何Rome III腹痛相关功能性胃肠病和肠易激综合征的风险因素。
- 幼儿期复发性腹痛与青春期结局无显著关联。
研究设计与样本
- 前瞻性基于人群的出生队列研究,纳入1994至1996年出生于瑞典的4089名儿童。
- 分析2455名在1、2、12和16岁有完整随访且12或16岁无家长报告炎症性肠病或乳糜泻诊断的儿童。
- 亚组2374名儿童在16岁回答了基于Rome III标准的问题。
主要发现
- 26.2%的儿童在3个评估点中至少1个报告复发性腹痛,其中11.3%报告症状超过一次。
- 12岁有复发性腹痛的儿童中44.9%在16岁症状持续。
- 12岁复发性腹痛儿童16岁时复发性腹痛相对风险2.2(95%CI 1.7-2.8)。
- 12岁复发性腹痛儿童16岁时任何腹痛相关功能性胃肠病相对风险2.6(95%CI 1.9-3.6)。
- 12岁复发性腹痛儿童16岁时肠易激综合征相对风险3.2(95%CI 2.0-5.1)。
关键数值与推荐
- 复发性腹痛在幼儿期(1-2岁)定义为家长报告的腹绞痛发作,在12岁和16岁定义为自我报告的每周腹痛。
- 16岁时腹痛相关功能性胃肠病根据Rome III标准定义。
临床怎么用
- 对12岁复发性腹痛儿童应关注症状持续及发展为功能性胃肠病或肠易激综合征的风险。
- 幼儿期复发性腹痛对青春期结局的预测价值有限,无需过度干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about the natural history of childhood recurrent abdominal pain (RAP). We investigated the prevalence and progression of childhood RAP and its association with Rome III abdominal pain-related functional gastrointestinal disorders (AP-FGID) and irritable bowel syndrome (IBS) during adolescence. METHODS: We collected data from a prospective population-based birth cohort study of 4089 children, born from 1994 through 1996 in Sweden. We analyzed data from 2455 children with complete follow-up evaluation at ages 1, 2, 12, and 16 years and no parent-reported diagnoses of inflammatory bowel diseases or celiac disease at ages 12 or 16 years. A subpopulation of 2374 children who had answered questions based on the Rome III criteria at age 16 years was identified. We assessed RAP at 3 assessment points and defined it as parent-reported attacks of colic in early childhood (1-2 years) and as self-reported weekly abdominal pain at ages 12 years and 16 years. AP-FGID at age 16 years was defined according to the Rome III criteria. RESULTS: RAP was reported by 26.2% of children on at least 1 of 3 assessment points, of which 11.3% reported symptoms more than once. Children with RAP at 12 years had persistent symptoms at 16 years in 44.9% of cases and increased risks for RAP (relative risk, 2.2; 95% CI, 1.7-2.8), any AP-FGID (relative risk, 2.6; 95% CI, 1.9-3.6), and IBS (relative risk, 3.2; 95% CI, 2.0-5.1) at 16 years. Early childhood RAP was not associated significantly with any outcome. CONCLUSIONS: RAP affects many children from early childhood through age 16 years, but most children do not have persistent symptoms throughout childhood. RAP at age 12 years is a risk factor for RAP, any Rome III AP-FGID, and IBS, at age 16 years.
引用
- Sjölund J, Uusijärvi A, Tornkvist NT, et al. Prevalence and Progression of Recurrent Abdominal Pain, From Early Childhood to Adolescence. Clin Gastroenterol Hepatol. 2020. PMID: 32344151. doi:10.1016/j.cgh.2020.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。